Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 5/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1591439 | 0.93 | KMT2A (0.52) | KMT2AMEN1KDM4EHPGDLMNA | |
| SCHEMBL13047073 | 0.89 | ALDH1A1 (0.46) | KDM4EHPGDLMNAPOLBALDH1A1 | |
| SCHEMBL13047060 | 0.89 | ALDH1A1 (0.53) | KMT2AMEN1KDM4EHPGDLMNA | |
| SCHEMBL13047063 | 0.88 | GRM2 (0.53) | KDM4EHPGDLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL13047067 | 0.86 | ALDH1A1 (0.58) | KDM4EHPGDLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL13047128 | 0.85 | POLB (0.56) | KMT2AKDM4EHPGDLMNAPOLB | |
| SCHEMBL1590729 | 0.84 | KMT2A (0.52) | KMT2AMEN1KDM4EHPGDLMNA | |
| SCHEMBL13047054 | 0.83 | MAPT (0.46) | KMT2AMEN1KDM4EHPGDLMNA | |
| SCHEMBL13047117 | 0.83 | TP53 (0.45) | KDM4EHPGDSMN1; SMN2MAPK8MAPK9 | |
| SCHEMBL13046857 | 0.83 | POLB (0.55) | KMT2AMEN1KDM4EHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546579-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | EVOTEC (US) INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546579-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | EVOTEC (US) INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20100292235-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | SECOND GENOME, INC. | 2010-11-18 | — | — | US | disclosed |
| US-20100292235-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | SECOND GENOME, INC. | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292235-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | KMT2A 4614/4885MEN1 4853/4885KDM4E 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.